Novigenix
17.1.2024 08:02:15 CET | ACCESS Newswire | Press release
GENEVA, SWITZERLAND / ACCESSWIRE / January 17, 2024 / With cancer projected to escalate to 29 million cases by 2040[1], Novigenix, a pioneer in AI healthcare solutions, is rewriting the rules of cancer care. Their newest innovation, LITOSeek™, is primed to reshape drug development, offering a transformative leap forward.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Personalized Cancer Treatment: Breaking Barriers
Every cancer is as unique as the person it affects. Tumors are in continuous dynamic interplay with the patient's immune defenses and are adept at subverting and escaping immune control. Novigenix is on a mission to improve the cancer treatment landscape, leveraging advanced AI and RNA analysis from a routine blood draw to provide more precise insights into patient immune responses to cancer treatments, compared to conventional DNA liquid biopsies that evaluate tumor evolution through circulating tumor DNA (ctDNA). Insights into the precise dynamic of patient immune response thus pave the way for superior therapeutic discoveries in the field.
Empowering Biopharma: Unveiling LITOSeek™ at Precision Medicine World Conference
On January 24th at the Precision Medicine World Conference in Silicon Valley, Novigenix will debut LITOSeek™, a groundbreaking solution designed to expedite drug development for biopharma companies.
AI and RNA Analysis: Pioneering Healthcare Transformation
With a decade-long track record, Novigenix successfully launched Colox® blood test in Switzerland, powered by AI and RNA analysis to detect early-stage colon cancer, marking a significant departure from invasive colonoscopy procedures. By aggregating data from diverse colon cancer patients, Novigenix identified immune system biomarkers crucial for early-stage detection, enhancing treatment outcomes.
Dr. Brian Hashemi, Novigenix's CEO and Chairman, emphasized, "Our experience with Colox® underscores the potential of AI RNA analysis. Ongoing studies across various cancer types have fuelled our Knowledge Base to uncover comprehensive sets of biomarkers via liquid biopsy and AI RNA analysis. Our validated immunotherapy response biomarkers provide early prediction of patient response and we invite biopharma companies to leverage our platform for more efficient and effective drug development."
Professor Pedro Romero, M.D. Chief Medical & Scientific Officer of Novigenix, and Founding Chief Editor of the Journal of Immunotherapy of Cancer, highlights the importance of patient immune response in the development of novel therapies: "AI RNA analysis is poised to revolutionize healthcare, accelerating conventional experimental drug development with data-driven precision immune response prediction. By swiftly analyzing systemic immune responses, AI compresses analysis times, expediting traditional drug development and powering discovery of novel therapy targets."
A Team Dedicated to the Future of Cancer Care
With over 20 Ph.D.-level scientists focused on the development of the LITOSeek™ platform and advancing next-generation liquid biopsy solutions, Novigenix is pioneering precision immunology to help transform cancer treatment paradigms for better patient outcomes.
#Ends#
[1] https://canceratlas.cancer.org/the-burden/the-burden-of-cancer/
Contact Information
Edwin Shankar
edwin.shankar@leidar.com
SOURCE: Novigenix
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Datavault AI Highlights Data Futures Platform Patent Amid Tokenized Stock Exemption15.10.2026 19:25:00 CEST | Press release
PHILADELPHIA, PA / ACCESS Newswire / October 15, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real-world asset ("RWA") tokenization technologies, today announced that the U.S. Patent and Trademark Office has issued a notice of allowance for its Method and System for Data Futures Platform patent application (U.S. Patent Application No. 17/441,847), and highlighted the relevance of the disclosed technology to a significant development in the regulatory landscape for tokenized securities. On September 17, 2026, the U.S. Securities and Exchange Commission announced a temporary, conditional "Innovation Exemption" intended to facilitate on-chain trading of certain tokenized National Market System stocks through qualifying Tokenized Securities Venues. The action represents a meaningful regulatory development for market participants exploring blockchain-based securities infrastructure, subject
Valsoft's TAG Software Group Acquires Positive Solutions, a UK Provider of Healthcare and Pharmacy Software15.10.2026 17:00:00 CEST | Press release
MONTRÉAL, QC / ACCESS Newswire / October 15, 2026 / Valsoft Corporation Inc. ("Valsoft"), a Canadian company specializing in the acquisition and long-term development of vertical market software businesses, today announced the acquisition of Positive Solutions Limited ("Positive Solutions"), a UK-based provider of pharmacy management and point-of-sale software for community pharmacies. The acquisition was completed through TAG Software Group, a wholly owned subsidiary of Valsoft. Founded in 1993 and headquartered in Adlington, UK, Positive Solutions provides integrated software that community pharmacies use to dispense medicine and run their retail operations. Its core products, Analyst PMR (patient medication record) and Analyst EPoS (electronic point of sale), support pharmacies ranging from single-site locations to large corporations. The company serves more than 2,500 sites across England, Scotland, and Wales. With this acquisition, TAG Software Group strengthens Valsoft's presence
OMP and Eastman Show Decision Velocity in Practice at Gartner Supply Chain Planning Summit 202615.10.2026 15:00:00 CEST | Press release
ATLANTA, GA / ACCESS Newswire / October 15, 2026 / OMP, a leader in AI-powered supply chain planning, is bringing Eastman to the Gartner Supply Chain Planning Summit 2026 in Denver, CO (November 2-3) to showcase decision velocity in practice. The global specialty materials company will show how it connected its long-term, mid-term, and short-term planning horizons into one cycle. Eastman on connecting its planning horizons In a session at the summit, Sachin Kothari, Manager IBP Excellence at Eastman, and Abhi Patel, Chief Business Operations Officer at OMP, will explain how Eastman moved from three planning horizons that each ran on their own schedule to one connected cycle linking long-, mid-, and short-term planning on a shared view of the value chain. The session also covers what got in the way of the shift and closes with the impact Eastman measured, along with recommendations for supply chain leaders whose planning still relies on handoffs. Meet OMP and explore planning transforma
Innodata to Report Third Quarter 2026 Results15.10.2026 14:05:00 CEST | Press release
NEW YORK, NY / ACCESS Newswire / October 15, 2026 / INNODATA INC. (Nasdaq:INOD) today announced that it will report Third Quarter 2026 results after the market closes on Thursday, November 5, 2026. A news release will be available in both the News and Investor Relations sections of the Innodata website, www.innodata.com. Innodata has scheduled an investor conference call for 5:00 PM Eastern time on that same day. The call-in numbers for the conference call are:(+1) 833 296 5777 North America, Toll Free(+44) 808 196 8935 United Kingdom(+1) 206 407 3228 InternationalParticipant Access Code 730 768 717 For Replay: (+1) 833 309 1852 North America-Toll Free(+44) 800 007 4044 United Kingdom(+1) 929 828 5978 InternationalAccess Code 730 768 717 Investors are also invited to access a live Webcast of the conference call at the Investor Relations section of Innodata's website at https://investor.innodata.com/events-and-presentations/. Please note that the Webcast feature will be in listen-only m
Karbon-X (OTCQB:KARX) Secures €1.88 Million (US$2.18 Million) in Net Trading Margin Through New European Low-Carbon Fuel Contracts15.10.2026 13:45:00 CEST | Press release
CALGARY, AB / ACCESS Newswire / October 15, 2026 / Karbon-X Corp. (OTCQB:KARX) ("Karbon-X" or the "Company"), a global carbon and environmental markets company, today announced that it has established new commercial capabilities and contracted activity across European low-carbon fuels and environmental markets during the first quarter of fiscal 2027. During the first quarter, Karbon‑X secured European low-carbon fuel contracts representing approximately €1.88 million (US$2.18 million) in net trading margin based on the agreed transaction economics. The Company has also secured additional contracted activity extending beyond fiscal 2027, supporting the continued development of its European business. Europe's decarbonization agenda is increasingly moving from broad policy objectives into sector-specific regulatory frameworks. The European Union's Renewable Energy Directive, together with related sector-specific regulations, is accelerating demand for renewable and low-carbon energy and s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom